Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Merz Pharma offers to buy Obagi Medical Products for $383.6mm; outbid by Valeant

Executive Summary

In an effort to outbid Valeant Pharmaceuticals International Inc., Merz GMBH & Co. KGAA's Merz Pharma Group (neurological and aesthetic dermatology products) has offered to acquire dermatology firm Obagi Medical Products Inc. for $22 per share in cash (a 54% premium), for a total of $383.6mm. Valeant had offered $19.75 ($344.3mm altogether).
Deal Industry
  • Pharmaceuticals
  • Pharmaceuticals
    • OTC, Consumer
Deal Status
  • Withdrawn
Deal Type
  • Acquisition
    • Full Acquisition
    • Payment Includes Cash

Related Companies